Emerging trends in the immunotherapy of pancreatic cancer

Kasturi Banerjee, Sushil Kumar, Kathleen A. Ross, Shailendra Gautam, Brittany Poelaert, Mohd W Nasser, Abhijit Aithal, Rakesh Bhatia, Michael J. Wannemuehler, Balaji Narasimhan, Joyce C Solheim, Surinder Kumar Batra, Maneesh Jain

Research output: Contribution to journalShort survey

6 Citations (Scopus)

Abstract

Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the U.S., claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the host immune surveillance by manipulating immune cells to establish an immunosuppressive tumor microenvironment (TME). Therefore, targeting and reinstating the patient's immune system could serve as a powerful therapeutic tool. Indeed, immunotherapy has emerged in recent years as a potential adjunct treatment for solid tumors including PC. Immunotherapy modulates the host's immune response to tumor-associated antigens (TAAs), eradicates cancer cells by reducing host tolerance to TAAs and provides both short- and long-term protection against the disease. Passive immunotherapies like monoclonal antibodies or engineered T-cell based therapies directly target tumor cells by recognizing TAAs. Active immunotherapies, like cancer vaccines, on the other hand elicit a long-lasting immune response via activation of the patient's immune cells against cancer cells. Several immunotherapy strategies have been tested for anti-tumor responses alone and in combination with standard care in multiple preclinical and clinical studies. In this review, we discuss various immunotherapy strategies used currently and their efficacy in abrogating self-antigen tolerance and immunosuppression, as well as their ability to eradicate PC.

Original languageEnglish (US)
Pages (from-to)35-46
Number of pages12
JournalCancer Letters
Volume417
DOIs
StatePublished - Mar 28 2018

Fingerprint

Pancreatic Neoplasms
Immunotherapy
Neoplasm Antigens
Neoplasms
Active Immunotherapy
Cancer Vaccines
Passive Immunization
Tumor Microenvironment
Autoantigens
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Immunosuppression
Immune System
Monoclonal Antibodies
T-Lymphocytes
Therapeutics

Keywords

  • Immunotherapy
  • Pancreatic cancer
  • PD-L1
  • Tumor associated antigen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Emerging trends in the immunotherapy of pancreatic cancer. / Banerjee, Kasturi; Kumar, Sushil; Ross, Kathleen A.; Gautam, Shailendra; Poelaert, Brittany; Nasser, Mohd W; Aithal, Abhijit; Bhatia, Rakesh; Wannemuehler, Michael J.; Narasimhan, Balaji; Solheim, Joyce C; Batra, Surinder Kumar; Jain, Maneesh.

In: Cancer Letters, Vol. 417, 28.03.2018, p. 35-46.

Research output: Contribution to journalShort survey

Banerjee, K, Kumar, S, Ross, KA, Gautam, S, Poelaert, B, Nasser, MW, Aithal, A, Bhatia, R, Wannemuehler, MJ, Narasimhan, B, Solheim, JC, Batra, SK & Jain, M 2018, 'Emerging trends in the immunotherapy of pancreatic cancer' Cancer Letters, vol. 417, pp. 35-46. https://doi.org/10.1016/j.canlet.2017.12.012
Banerjee, Kasturi ; Kumar, Sushil ; Ross, Kathleen A. ; Gautam, Shailendra ; Poelaert, Brittany ; Nasser, Mohd W ; Aithal, Abhijit ; Bhatia, Rakesh ; Wannemuehler, Michael J. ; Narasimhan, Balaji ; Solheim, Joyce C ; Batra, Surinder Kumar ; Jain, Maneesh. / Emerging trends in the immunotherapy of pancreatic cancer. In: Cancer Letters. 2018 ; Vol. 417. pp. 35-46.
@article{a11efa11a26941f087a611cbd060566e,
title = "Emerging trends in the immunotherapy of pancreatic cancer",
abstract = "Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the U.S., claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the host immune surveillance by manipulating immune cells to establish an immunosuppressive tumor microenvironment (TME). Therefore, targeting and reinstating the patient's immune system could serve as a powerful therapeutic tool. Indeed, immunotherapy has emerged in recent years as a potential adjunct treatment for solid tumors including PC. Immunotherapy modulates the host's immune response to tumor-associated antigens (TAAs), eradicates cancer cells by reducing host tolerance to TAAs and provides both short- and long-term protection against the disease. Passive immunotherapies like monoclonal antibodies or engineered T-cell based therapies directly target tumor cells by recognizing TAAs. Active immunotherapies, like cancer vaccines, on the other hand elicit a long-lasting immune response via activation of the patient's immune cells against cancer cells. Several immunotherapy strategies have been tested for anti-tumor responses alone and in combination with standard care in multiple preclinical and clinical studies. In this review, we discuss various immunotherapy strategies used currently and their efficacy in abrogating self-antigen tolerance and immunosuppression, as well as their ability to eradicate PC.",
keywords = "Immunotherapy, Pancreatic cancer, PD-L1, Tumor associated antigen",
author = "Kasturi Banerjee and Sushil Kumar and Ross, {Kathleen A.} and Shailendra Gautam and Brittany Poelaert and Nasser, {Mohd W} and Abhijit Aithal and Rakesh Bhatia and Wannemuehler, {Michael J.} and Balaji Narasimhan and Solheim, {Joyce C} and Batra, {Surinder Kumar} and Maneesh Jain",
year = "2018",
month = "3",
day = "28",
doi = "10.1016/j.canlet.2017.12.012",
language = "English (US)",
volume = "417",
pages = "35--46",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Emerging trends in the immunotherapy of pancreatic cancer

AU - Banerjee, Kasturi

AU - Kumar, Sushil

AU - Ross, Kathleen A.

AU - Gautam, Shailendra

AU - Poelaert, Brittany

AU - Nasser, Mohd W

AU - Aithal, Abhijit

AU - Bhatia, Rakesh

AU - Wannemuehler, Michael J.

AU - Narasimhan, Balaji

AU - Solheim, Joyce C

AU - Batra, Surinder Kumar

AU - Jain, Maneesh

PY - 2018/3/28

Y1 - 2018/3/28

N2 - Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the U.S., claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the host immune surveillance by manipulating immune cells to establish an immunosuppressive tumor microenvironment (TME). Therefore, targeting and reinstating the patient's immune system could serve as a powerful therapeutic tool. Indeed, immunotherapy has emerged in recent years as a potential adjunct treatment for solid tumors including PC. Immunotherapy modulates the host's immune response to tumor-associated antigens (TAAs), eradicates cancer cells by reducing host tolerance to TAAs and provides both short- and long-term protection against the disease. Passive immunotherapies like monoclonal antibodies or engineered T-cell based therapies directly target tumor cells by recognizing TAAs. Active immunotherapies, like cancer vaccines, on the other hand elicit a long-lasting immune response via activation of the patient's immune cells against cancer cells. Several immunotherapy strategies have been tested for anti-tumor responses alone and in combination with standard care in multiple preclinical and clinical studies. In this review, we discuss various immunotherapy strategies used currently and their efficacy in abrogating self-antigen tolerance and immunosuppression, as well as their ability to eradicate PC.

AB - Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the U.S., claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the host immune surveillance by manipulating immune cells to establish an immunosuppressive tumor microenvironment (TME). Therefore, targeting and reinstating the patient's immune system could serve as a powerful therapeutic tool. Indeed, immunotherapy has emerged in recent years as a potential adjunct treatment for solid tumors including PC. Immunotherapy modulates the host's immune response to tumor-associated antigens (TAAs), eradicates cancer cells by reducing host tolerance to TAAs and provides both short- and long-term protection against the disease. Passive immunotherapies like monoclonal antibodies or engineered T-cell based therapies directly target tumor cells by recognizing TAAs. Active immunotherapies, like cancer vaccines, on the other hand elicit a long-lasting immune response via activation of the patient's immune cells against cancer cells. Several immunotherapy strategies have been tested for anti-tumor responses alone and in combination with standard care in multiple preclinical and clinical studies. In this review, we discuss various immunotherapy strategies used currently and their efficacy in abrogating self-antigen tolerance and immunosuppression, as well as their ability to eradicate PC.

KW - Immunotherapy

KW - Pancreatic cancer

KW - PD-L1

KW - Tumor associated antigen

UR - http://www.scopus.com/inward/record.url?scp=85039801505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039801505&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2017.12.012

DO - 10.1016/j.canlet.2017.12.012

M3 - Short survey

VL - 417

SP - 35

EP - 46

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -